Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: Immune-related histologic phenotype in pretreatment tumour biopsy predicts the efficacy of neoadjuvant anti-PD-1 treatment in squamous lung cancer

Fig. 1

Histopathologic assessment of response to treatment in resected samples: the influence of the calculation of %RVT with and without necrosis and emphasizing the assessment of the histologic phenotype of RVT cells. Whether %RVT was calculated with or without necrosis had almost no effect on the consistency of pathologic assessment and the pathologic response group, except for patient 14, whose group changed from MPR to partial pathologic response (pPR) (A) with a mean value changing from 10 to 25% (C). The mean ± SD of %RVT with immune-activated phenotype for each case is shown in B. The interpathologist variability of assessing %RVT with immune-activated phenotype was not statistically significant (P = 0.480) (D)

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us